SK Plasma Launches High-Dose Revolpag 75 mg to Simplify Thrombocytopenia Regimens and Cut Costs
SK Plasma announced on Sept. 1 that it has begun distributing Revolpag Tablets 75 mg in South Korea, expanding its lineup following the August...
Search results for "immune cell therapy"
Gachon University Gil Medical Center Expands Advanced Blood Cancer Care as Regional CAR-T Center Reaches Two-Year Milestone
For patients with aggressive blood cancers that recur or fail to respond to standard chemotherapy, chimeric antigen receptor T-cell (CAR-T)...
Why Skin Barriers Collapse in Atopic Dermatitis: Researchers Identify Rogue Protein Pair
Why does the skin of patients with atopic dermatitis become dry so easily and react with heightened sensitivity to even...
Same Arthritis Drug, Different Results: Why Treatment Nonresponse Is Not Your Fault
If two patients take the exact same medication, why does one recover while the other sees little to no improvement.
More Stem Cells Doesn't Mean Better Results: Why Cell Count Alone Falls Short
Following the box-office success of the film Spider-Man: Brand New Day, public attention has once again turned to...
Samsung Bioepis Seeks South Korean Approval for Keytruda Biosimilar SB27
Samsung Bioepis announced on Aug. 10 that it has submitted a marketing authorization application to South Korea's...
Timing of Immune Cell Entry Dictates Anti-Cancer Defense in Hard-to-Treat Brain Tumors
Some immune cells surrounding a tumor actively attack it, while others create conditions that help it survive.
Prevention vs. Treatment: Why Cancer Therapy Demands a Completely Different Diet
What makes diabetes particularly dangerous is the risk of severe, systemic complications.
The Blood Cancer Decoy: Why Some Lymphoma Patients Stop Responding to Treatment
For patients diagnosed with aggressive blood cancers, receiving a proven targeted therapy offers a clear path toward a...
HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data
HLB Innovation announced on July 23 that its U.S. subsidiary, Verismo Therapeutics, has expanded the Phase 1 clinical...